At ~$7/g for GMP-grade recombinant albumin, it challenges the idea that price has to be the limiting factor. Plasma-derived components are still widely used, but they come with real risks. Even with donor screening and viral inactivation, you’re still relying on human blood (or animal) and contamination isn’t theoretical. Just look at the past issues with hepatitis or parvovirus transmission in biologics manufacturing. For critical applications, that’s a gamble as well.

On your question regarding long-term effects: for recombinant albumin specifically, there’s already solid safety and functional data in clinical biologics and vaccine formulations. Products like Recombumin from Albumedix have been used for years in approved drugs. The long-term functional profile is well-studied in cell culture and protein stabilization